Phase II Study of Oxaliplatin, 5-fluorouracil, and Leucovorin in Relapsed or Metastatic Colorectal Cancer as Second Line Therapy / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
; : 201-205, 2006.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-115209
Responsible library:
WPRO
ABSTRACT
PURPOSE:
The purpose of the study was to assess the efficacy and safety of biweekly oxaliplatin in combination with leucovorin (LV)-modulated bolus plus infusion of 5-fluorouracil (5-FU) in patients with relapsed or metastatic colorectal cancer (CRC) as a second line therapy. MATERIALS ANDMETHODS:
Between November 2002 and October 2005, 26 patients with histologically confirmed relapsed or metastatic CRC were enrolled. All patients were previously treated with irinotecan-based combination chemotherapy. The chemotherapy regimen consisted of oxaliplatin 85 mg/m2 on day 1; LV 200 mg/m2 on days 1 and 2; and 5-FU 400 mg/m2 bolus IV with 600 mg/m2 with a 22-hour infusion on days 1 and 2 every 2 weeks.RESULTS:
The median age of the 26 patients was 50.5 years (range, 31~72). Their metastatic sites included the liver (42.3%), peritoneum (26.9%), lung (23.1%) and ovary (7.7%). Twenty five patients were evaluated for their response. Four patients achieved partial responses and 15 patients had stable disease. The overall response rate was 16% (95% confidence interval; 1.7~30.3%). The median follow-up duration for the surviving patients was 7.4 months (range, 2.08~21.2). Median overall survival (OS) and 1-year OS rates were 16.7 months and 63.9%, respectively. The most common hematological toxicities were NCI grade I/II leucopenia (49.3%), grade I/II neutropenia (41%) and grade I/II anemia (65.2%). The main non-hematological toxicities were grade I/II peripheral neuropathy (16.1% and 21.5%, respectively) and nausea/ vomiting (23.6%/18.5%). There was no life-threatening toxicity.CONCLUSION:
The oxaliplatin, 5-FU and LV combination chemotherapy, scheduled as a biweekly protocol, was effective and well tolerated in the treatment of relapsed or metastatic colorectal cancer patients as second line chemotherapy.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Ovary
/
Peritoneum
/
Vomiting
/
Colorectal Neoplasms
/
Leucovorin
/
Follow-Up Studies
/
Peripheral Nervous System Diseases
/
Drug Therapy
/
Drug Therapy, Combination
/
Fluorouracil
Type of study:
Practice guideline
/
Observational study
/
Prognostic study
/
Risk factors
Limits:
Female
/
Humans
Language:
English
Journal:
Cancer Research and Treatment
Year:
2006
Document type:
Article